Search Results - Link, J.

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial by Martin, M., Holmes, F., Ejlertsen, B., Delaloge, S., Moy, B., Iwata, H., von Minckwitz, G., Chia, S., Mansi, J., Barrios, C., Gnant, M., Tomaševic, Z., Denduluri, N., Šeparovic, R., Gokmen, E., Bashford, A., Ruiz Borrego, M., Kim, S., Jakobsen, E., Ciceniene, A., Inoue, K., Overkamp, F., Heijns, J., Armstrong, A., Link, J., Joy, A., Bryce, R., Wong, A., Moran, S., Yao, B., Xu, F., Auerbach, A., Buyse, M., Chan, Arlene, ExteNET Study Group

Get full text